KOPS - The Institutional Repository of the University of Konstanz

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Aufgrund von Vorbereitungen auf eine neue Version von KOPS, können kommenden Montag und Dienstag keine Publikationen eingereicht werden. (Due to preparations for a new version of KOPS, no publications can be submitted next Monday and Tuesday.)

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Cite This

Files in this item

Files Size Format View

There are no files associated with this item.

STEMMER, Kerstin, Brian FINAN, Richard D. DIMARCHI, Matthias H. TSCHÖP, Timo D. MÜLLER, 2020. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. In: Advanced Drug Delivery Reviews. Elsevier. 159, pp. 34-53. ISSN 0169-409X. eISSN 1872-8294. Available under: doi: 10.1016/j.addr.2020.05.008

@article{Stemmer2020Insig-52377, title={Insights into incretin-based therapies for treatment of diabetic dyslipidemia}, year={2020}, doi={10.1016/j.addr.2020.05.008}, volume={159}, issn={0169-409X}, journal={Advanced Drug Delivery Reviews}, pages={34--53}, author={Stemmer, Kerstin and Finan, Brian and DiMarchi, Richard D. and Tschöp, Matthias H. and Müller, Timo D.} }

<rdf:RDF xmlns:dcterms="http://purl.org/dc/terms/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:void="http://rdfs.org/ns/void#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/52377"> <dc:creator>Tschöp, Matthias H.</dc:creator> <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:contributor>Müller, Timo D.</dc:contributor> <dcterms:abstract xml:lang="eng">Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.</dcterms:abstract> <dc:creator>Müller, Timo D.</dc:creator> <dc:contributor>Stemmer, Kerstin</dc:contributor> <dc:creator>Stemmer, Kerstin</dc:creator> <dc:contributor>Tschöp, Matthias H.</dc:contributor> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52377"/> <dcterms:issued>2020</dcterms:issued> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-01-13T10:53:47Z</dcterms:available> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-01-13T10:53:47Z</dc:date> <dc:creator>DiMarchi, Richard D.</dc:creator> <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/rdf/resource/123456789/28"/> <dc:creator>Finan, Brian</dc:creator> <dc:language>eng</dc:language> <dc:contributor>Finan, Brian</dc:contributor> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:contributor>DiMarchi, Richard D.</dc:contributor> <dcterms:title>Insights into incretin-based therapies for treatment of diabetic dyslipidemia</dcterms:title> </rdf:Description> </rdf:RDF>

This item appears in the following Collection(s)

Search KOPS


Browse

My Account